Forum

× click the New Topic button to post

New Guidelines On Non-muscle Invasive Bladder Cancer

12 years 6 months ago #10234 by Gracie
Patricia, I am currently receiving INF/BCG and am responding very well. It is not in the trial phase.

Brewster - it is an interesting omission.

Gracie

Please Log in or Create an account to join the conversation.

12 years 6 months ago #10217 by Patricia
I think Brewster that the combination of BCG and Interferon is still in maybe Phase 11 trials ...so possibly thats why its not mentioned?? Just a thought?

Please Log in or Create an account to join the conversation.

12 years 6 months ago #10185 by brewster
What's interesting to me about this report is the omission of the treatment combination of BCG (reduced dosage) + Interferon. From everything I've read and heard this combo has greater efficacy and lower toxicity than BCG alone. Why would it not get mentioned in a report like this? curious, brewster

Please Log in or Create an account to join the conversation.

12 years 6 months ago #10114 by Zachary
The American Urological Association has prepared a new Guideline on the Management of Nonmuscle Invasive Bladder Cancer for professionals.

http://www.sciencedaily.com/releases/2007/11/071109104726.htm

A quick summary:

The Guideline comes to the following conclusions based on current literature:

* Accurate clinical staging upon which to base treatment decisions is critically important. The panel recommends performing a repeat TURBT prior to intravesical therapy in situations where there is high grade T1 disease without muscularis propria in the specimen and in select cases even when there is muscle present.
* A single, post-operative instillation of a chemotherapeutic agent may decrease recurrence risk in patients with superficial disease who have undergone uncomplicated resection of the tumor(s).
* There is no clear superiority of immunotherapy over chemotherapy for low risk disease. Induction courses of either intravesical chemotherapy or immunotherapy (BCG) should be administered in patients with an increased risk of tumor recurrence but low risk of progression.
* An induction course of mitomycin C in conjunction with maintenance therapy enhances the effectiveness of the drug in preventing recurrence, however, no determinations have been made in regard to optimal maintenance dose, schedule or duration.
* An induction course of BCG in conjunction with maintenance BCG therapy decreases recurrence and possibly progression in patients with higher risk tumors. Though no determinations on optimal schedule and duration have been made, data is available that supports the SWOG regimen.

"Standing on my Head"---my chemo journal
T3a Grade 4 N+M0
RC at USC/Norris June 23, 2006 by Dr. John Stein

Please Log in or Create an account to join the conversation.

  • Not Allowed: to create new topic.
  • Not Allowed: to reply.
  • Not Allowed: to add Files.
  • Not Allowed: to edit your message.
Moderators: Cynthiaeddieksara.anne

Users

Total Online: 0 Users and 2230 Guests 

Statistics

Today Total Opened: 0 Today Total Answered: 2 Latest User: Firefly
Yesterday Total Opened: 2 Yesterday Total Answered: 5
Total Posts: 53690 Total Subjects: 7028 Total Users: 8726